Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SJ 733

Next Previous
Drug Profile

SJ 733

Alternative Names: (+)-SJ 000557733; SJ-557733; SJ-733

Latest Information Update: 14 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator St. Jude Childrens Research Hospital
  • Developer Eisai Co Ltd; Medicines for Malaria Venture; QIMR Berghofer Medical Research Institute; St. Jude Childrens Research Hospital; University of Kentucky
  • Class Amides; Antimalarials; Fluorobenzenes; Isoquinolines; Nitriles; Pyridines; Small molecules
  • Mechanism of Action PfATP4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Falciparum malaria; Vivax malaria
  • No development reported Malaria

Most Recent Events

  • 12 Aug 2024 Eisai, University of Kentucky and 60 Degrees Pharmaceuticals plans a phase-IIb trial for Vivax malaria (Combination therapy) in USA
  • 12 Aug 2024 University of Kentucky, Eisai and 60 Degrees Pharmaceuticals plans a pivotal phase-III trial for Vivax malaria (Combination therapy)
  • 28 Nov 2022 No recent reports of development identified for phase-I development in Malaria(In volunteers) in Australia (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top